Alpha cell: Difference between revisions

Latest revision as of 11:32, 21 October 2025

Template:Short description Template:Infobox cell Alpha cells (α-cells) are endocrine cells that are found in the Islets of Langerhans in the pancreas. Alpha cells secrete the peptide hormone glucagon in order to increase glucose levels in the blood stream.^[1]

Discovery

Islets of Langerhans were first discussed by Paul Langerhans in his medical thesis in 1869.^[2] This same year, Édouard Laguesse named them after Langerhans.^[3] At first, there was a lot of controversy about what the Islets were made of and what they did.^[3] It appeared that all of the cells were the same within the Islet, but were histologically distinct from acini cells.^[3] Laguesse discovered that the cells within the Islets of Langerhans contained granules that distinguished them from acini cells.^[3] He also determined that these granules were products of the metabolism of the cells in which they were contained.^[3] Michael Lane was the one to discover that alpha cells were histologically different than beta cells in 1907.^[3]

Before the function of alpha cells was discovered, the function of their metabolic product, glucagon, was discovered. The discovery of the function of glucagon coincides with the discovery of the function of insulin. In 1921, Banting and Best were testing pancreatic extracts in dogs that had had their pancreas removed. They discovered that "insulin-induced hypoglycemia was preceded by a transient, rather mild hyperglycemia..."^[4] Murlin is credited with the discovery of glucagon because in 1923 they suggested that the early hyperglycemic effect observed by Banting and Best was due to "a contaminant with glucogenic properties that they also proposed to call 'glucagon,' or the mobilizer of glucose".^[4] In 1948, Sutherland and de Duve established that alpha cells in the pancreas were the source of glucagon.^[4]

Anatomy

Alpha cells are endocrine cells, meaning they secrete a hormone, in this case glucagon. Alpha cells store this glucagon in secretory vesicles that typically have an electron dense core and a grayish outer edge.^[1] It is believed that alpha cells make up approximately 20% of endocrine cells within the pancreas.^[1] Alpha cells are most commonly found on the dorsal side of the pancreas and are very rarely found on the ventral side of the pancreas.^[1] Alpha cells are typically found in compact Islets of Langerhans, which are themselves typically found in the body of the pancreas.^[1]

Function

Alpha cells function in the maintenance of blood glucose levels. Alpha cells are stimulated to produce glucagon in response to hypoglycemia, epinephrine, amino acids, other hormones, and neurotransmitters.^[5]

Glucagon Secretion and Control of Gluconeogenesis

Glucagon functions to signal the liver to begin gluconeogenesis which increases glucose levels in the blood.^[5] Glucagon will bind to the glucagon receptors on the plasma membranes of hepatocytes (liver cells). This ligand binding causes the activation of adenylate cyclase, which causes the creation of cyclic AMP (cAMP).^[6] As the intracellular concentration of cAMP rises, protein kinase A (PKA) is activated and phosphorylates the transcription factor cAMP Response Element Binding (CREB) protein.^[6] CREB then induces transcription of glucose-6-phosphatase and phosphoenolpyruvate carboxylase (PEPCK). These enzymes increase gluconeogenic activity.^[6] PKA also phosphorylates phospho-fructokinase 2 (PFK2)/fructose 2,6-biphsophatase (FBPase2), inhibiting PFK2 and activating FBPase2.^[6] This inhibition decreases intracellular levels of fructose 2,6-biphosphate and increases intracellular levels of fructose 6-phosphate which decreases glycolytic activity and increases gluconeogenic activity.^[6] PKA also phosphorylates pyruvate kinase which causes an increase in intracellular levels of fructose 1,6-biphosphate and decreases intracellular levels of pyruvate, further decreasing glycolytic activity.^[6] The most important action of PKA in regulating gluconeogenesis is the phosphorylation of phosphorylase kinase which acts to initiate the glycogenolysis reaction, which is the conversion of glycogen to glucose, by converting glycogen to glucose 1-phosphate.^[6]

Alpha cells also generate Glucagon-like peptide-1 and may have protective and regenerative effect on beta cells. They possibly can transdifferentiate into beta cells to replace lost beta cells.^[7]

Regulation of glucagon secretion

There are several methods of control of the secretion of glucagon. The most well studied is through the action of extra-pancreatic glucose sensors, including neurons found in the brain and spinal cord, which exert control over the alpha cells in the pancreas.^[5] Indirect, non-neuronal control has also been found to influence secretion of glucagon.^[5]

Neuronal Control

The most well studied is through the action of extra-pancreatic glucose sensors, including neurons found in the brain, which exert control over the alpha cells in the pancreas.^[5] The pancreas is controlled by both the sympathetic nervous system and the parasympathetic nervous system, although the method these two systems use to control the pancreas appears to be different.^[8]

Sympathetic control of the pancreas appears to originate from the sympathetic preganglionic fibers in the lower thoracic and lumbar spinal cord.^[9] According to Travagli et al. "axons from these neurons exit the spinal cord through the ventral roots and supply either the paravertebral ganglia of the sympathetic chain via communicating rami of the thoracic and lumbar nerves, or the celiac and mesenteric ganglia via the splanchnic nerves. The catecholaminergic neurons of these ganglia innervate the intrapancreatic ganglia, islets and blood vessels..."^[9] The exact nature of the effect of sympathetic activation on the pancreas has been difficult to discern. However, a few things are known. It appears that stimulation of the splanchnic nerve lowers plasma insulin levels possibly through the action of α2 adrenoreceptors on beta cells.^[9] It has also been shown that stimulation of the splanchnic nerve increases glucagon secretion.^[9] Both of these findings together suggest that sympathetic stimulation of the pancreas is meant to maintain blood glucose levels during heightened arousal.^[9]

Parasympathetic control of the pancreas appears to originate from the Vagus nerve.^[8] Electrical and pharmacological stimulation of the Vagus nerve increases secretion of glucagon and insulin in most mammalian species, including humans. This suggests that the role of parasympathetic control is to maintain normal blood glucose concentration under normal conditions.^[8]

Non-neuronal Control

Non-neuronal control has been found to be indirect paracrine regulation through ions, hormones, and neurotransmitters. Zinc, insulin, serotonin, γ-aminobutyric acid, and γ-hydroxybutyrate, all of which are released by beta cells in the pancreas, have been found to suppress glucagon production in alpha cells.^[5] Delta cells also release somatostatin which has been found to inhibit glucagon secretion.^[5]

Zinc is secreted at the same time as insulin by the beta cells in the pancreas. It has been proposed to act as a paracrine signal to inhibit glucagon secretion in alpha cells. Zinc is transported into both alpha and beta cells by the zinc transporter ZnT8. This protein channel allows zinc to cross the plasma membrane into the cell. When ZnT8 is under-expressed, there is a marked increase in glucagon secretion. When ZnT8 is over-expressed, there is a marked decrease in glucagon secretion. The exact mechanism by which zinc inhibits glucagon secretion is not known.^[10]

Insulin has been shown to function as a paracrine signal to inhibit glucagon secretion by the alpha cells.^[11] However, this is not through a direct interaction. It appears that insulin functions to inhibit glucagon secretion through activation of delta cells to secrete somatostatin.^[12] Insulin binds to SGLT2 causing an increased glucose uptake into delta cells. SGLT2 is a sodium and glucose symporter, meaning that it brings glucose and sodium ions across the membrane at the same time in the same direction. This influx of sodium ions, in the right conditions, can cause a depolarization event across the membrane. This opens calcium channels, causing intracellular calcium levels to increase. This increase in the concentration of calcium in the cytosol activates ryanodine receptors on the endoplasmic reticulum which causes the release of more calcium into the cytosol. This increase in calcium causes the secretion of somatostatin by the delta cells.^[12]

Somatostatin inhibits glucagon secretion through the activation of SSTR2, a membrane bound protein that when activated causes a hyperpolarization of the membrane. This hyperpolarization causes voltage gated calcium channels to close, leading to a decrease in intracellular calcium levels. This causes a decrease in exocytosis. In the case of alpha cells, this causes a decrease in the secretion of glucagon.^[13]

Serotonin inhibits the secretion of glucagon through its receptors on the plasma membrane of alpha cells. Alpha cells have 5-HT1f receptors which are triggered by the binding of serotonin. Once activated, these receptors suppress the action of adenylyl cyclase, which suppresses the production of cAMP. The inhibition of the production of cAMP in turn suppresses the secretion of glucagon.^[5] Serotonin is considered a paracrine signal due to the close proximity of beta cells to alpha cells.^[14]

Glucose can also have a somewhat direct influence on glucagon secretion as well. This is through the influence of ATP. Cellular concentrations of ATP directly reflects the concentration of glucose in the blood. If the concentration of ATP drops in alpha cells, this causes potassium ion channels in the plasma membrane to close. This causes depolarization across the membrane causing calcium ion channels to open, allowing calcium to flood into the cell. This increase in the cellular concentration of calcium causes secretory vesicles containing glucagon to fuse with the plasma membrane, thus causing the secretion of glucagon from the pancreas.^[5]

Medical significance

High levels of glucagon secretion has been implicated in both Type I and Type II diabetes. In fact, high levels of plasma glucagon is considered an early sign of the development of both Type I and Type II diabetes.^[15]

Type I Diabetes

It is thought that high glucagon levels and lack of insulin production are the main triggers for the metabolic issues associated with Type I diabetes, in particular maintaining normal blood glucose levels, formation of ketone bodies, and formation of urea.^[16] One finding of note is that the glucagon response to hypoglycemia is completely absent in patients with Type I diabetes.^[16] Consistently high glucagon concentrations in the blood can lead to diabetic ketoacidosis,^[16] which is when ketones from lipid breakdown build up in the blood, which can lead to dangerously low blood glucose levels, low potassium levels, and in extreme cases cerebral edema.^[17] It has been proposed that the reason for the high levels of glucagon found in the plasma of patients with Type I diabetes is the absence of beta cells producing insulin and the reciprocal effect this has on delta cells and the secretion of somatostatin.^[16]

Type II Diabetes

Patients with Type II diabetes will have elevated glucagon levels during a fast and after eating.^[18] These elevated glucagon levels over stimulate the liver to undergo gluconeogenesis, leading to elevated blood glucose levels.^[18] Consistently high blood glucose levels can lead to organ damage, neuropathy, blindness, cardiovascular issues and bone and joint problems.^[19] It is not entirely clear why glucagon levels are so high in patients with Type II diabetes. One theory is that the alpha cells have become resistant to the inhibitory effects of glucose and insulin and do not respond properly to them.^[18] Another theory is that nutrient stimulation of the gastrointestinal tract, thus the secretion of gastric inhibitory polypeptide and Glucagon-like peptide-1, is a very important factor in the elevated secretion of glucagon.^[18]

In other species

There is much controversy as to the effects of various artemisinin derivatives on α-cell-to-β-cell differentiation in rodents and zebrafish.Template:Rr Li et al., 2017 find artemisinin itself forces α⇨β conversion in rodents (via gephyrin)Template:Rr and zebrafishTemplate:Rr while Ackermann et al., 2018 find artesunate does notTemplate:Rr and van der Meulen et al., 2018 find the same absence of effect for artemether Template:Rr (although artemether does inhibit ARX).Template:Rr (Shin et al., 2019 further finds no such effect for GABA in rhesus macaque, although GABA is not an artemisinin but has a related action.)Template:Rr Both Eizirik & Gurzov 2018^[20] and Yi et al., 2020^[21] consider it possible that these are all legitimately varying results from varying combinations of substance, subject, and environment. On the other hand, a large number of reviewersTemplate:Rr are uncertain whether these are separate effects, instead questioning the validity of Li on the basis of Ackermann and van der Meulen – perhaps GABA receptor agonists as a whole are not β-cell-ergic.Template:Rr Coppieters et al., 2020 goes further, highlighting Ackermann and van der Meulen as publications that catch an unreplicatable scientific result, Li.^[22]

References

↑ ^a ^b ^c ^d ^e Script error: No such module "citation/CS1".
↑ Script error: No such module "Citation/CS1".
↑ ^a ^b ^c ^d ^e ^f Script error: No such module "Citation/CS1".
↑ ^a ^b ^c Script error: No such module "Citation/CS1".
↑ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ Script error: No such module "Citation/CS1".
↑ ^a ^b ^c ^d ^e ^f ^g Script error: No such module "Citation/CS1".
↑ Script error: No such module "Citation/CS1".
↑ ^a ^b ^c Script error: No such module "Citation/CS1".
↑ ^a ^b ^c ^d ^e Script error: No such module "Citation/CS1".
↑ Script error: No such module "Citation/CS1".
↑ Script error: No such module "Citation/CS1".
↑ ^a ^b Script error: No such module "Citation/CS1".
↑ Script error: No such module "Citation/CS1".
↑ Script error: No such module "Citation/CS1".
↑ Script error: No such module "citation/CS1".
↑ ^a ^b ^c ^d Script error: No such module "Citation/CS1".
↑ Script error: No such module "citation/CS1".
↑ ^a ^b ^c ^d Script error: No such module "Citation/CS1".
↑ Script error: No such module "citation/CS1".
↑ Cite error: Script error: No such module "Namespace detect".Script error: No such module "Namespace detect".
↑ Cite error: Script error: No such module "Namespace detect".Script error: No such module "Namespace detect".
↑ Cite error: Script error: No such module "Namespace detect".Script error: No such module "Namespace detect".

@@ Line 15: / Line 15: @@
 == Discovery ==
-Islets of Langerhans were first discussed by Paul Langerhans in his medical thesis in 1869.<ref>{{Cite journal |last=Jörgens |first=Viktor |date=2020 |title=Paul Langerhans: The Man Who Discovered the Islets |url=https://www.karger.com/Article/FullText/506551 |journal=Unveiling Diabetes - Historical Milestones in Diabetology |series=Frontiers in Diabetes |language=english |volume=29 |pages=25–35 |doi=10.1159/000506551|isbn=978-3-318-06733-0 |s2cid=226502826 |url-access=subscription }}</ref> This same year, [[Édouard Laguesse]] named them after Langerhans.<ref name=":1">{{Cite journal |last=Lane |first=Michael |date=1907 |title=The Cytological Characters of the Areas of Langerhans |journal=The American Journal of Anatomy |volume=VII |issue=3 |pages=409–422|doi=10.1002/aja.1000070304 |url=https://www.biodiversitylibrary.org/item/70305 |hdl=2027/mdp.39015067353063 |hdl-access=free }}</ref> At first, there was a lot of controversy about what the Islets were made of and what they did.<ref name=":1" /> It appeared that all of the cells were the same within the Islet, but were histologically distinct from acini cells.<ref name=":1" /> Laguesse discovered that the cells within the Islets of Langerhans contained granules that distinguished them from acini cells.<ref name=":1" /> He also determined that these granules were products of the metabolism of the cells in which they were contained.<ref name=":1" /> Michael Lane was the one to discover that alpha cells were histologically different than [[beta cell]]s in 1907.<ref name=":1" />
+Islets of Langerhans were first discussed by Paul Langerhans in his medical thesis in 1869.<ref>{{Cite journal |last=Jörgens |first=Viktor |date=2020 |title=Paul Langerhans: The Man Who Discovered the Islets |url=https://www.karger.com/Article/FullText/506551 |journal=Unveiling Diabetes - Historical Milestones in Diabetology |series=Frontiers in Diabetes |language=english |volume=29 |pages=25–35 |doi=10.1159/000506551|isbn=978-3-318-06733-0 |s2cid=226502826 |url-access=subscription }}</ref> This same year, [[Édouard Laguesse]] named them after Langerhans.<ref name=":1">{{Cite journal |last=Lane |first=Michael |date=1907 |title=The Cytological Characters of the Areas of Langerhans |journal=The American Journal of Anatomy |volume=VII |issue=3 |pages=409–422|doi=10.1002/aja.1000070304 |url=https://www.biodiversitylibrary.org/item/70305 |hdl=2027/mdp.39015067353063 |hdl-access=free }}</ref> At first, there was a lot of controversy about what the Islets were made of and what they did.<ref name=":1" /> It appeared that all of the cells were the same within the Islet, but were histologically distinct from [[acini]] cells.<ref name=":1" /> Laguesse discovered that the cells within the Islets of Langerhans contained granules that distinguished them from acini cells.<ref name=":1" /> He also determined that these granules were products of the metabolism of the cells in which they were contained.<ref name=":1" /> Michael Lane was the one to discover that alpha cells were histologically different than [[beta cell]]s in 1907.<ref name=":1" />
 Before the function of alpha cells was discovered, the function of their metabolic product, glucagon, was discovered. The discovery of the function of glucagon coincides with the discovery of the function of [[insulin]]. In 1921, Banting and Best were testing pancreatic extracts in dogs that had had their pancreas removed. They discovered that "insulin-induced hypoglycemia was preceded by a transient, rather mild hyperglycemia..."<ref name=":2">{{Cite journal |last1=Gromada |first1=Jesper |last2=Franklin |first2=Isobel |last3=Wollheim |first3=Claes B. |date=2007-02-01 |title=α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains |journal=Endocrine Reviews |language=en |volume=28 |issue=1 |pages=84–116 |doi=10.1210/er.2006-0007 |pmid=17261637 |issn=0163-769X|doi-access=free }}</ref> Murlin is credited with the discovery of glucagon because in 1923 they suggested that the early hyperglycemic effect observed by Banting and Best was due to "a contaminant with glucogenic properties that they also proposed to call 'glucagon,' or the mobilizer of glucose".<ref name=":2" /> In 1948, Sutherland and de Duve established that alpha cells in the pancreas were the source of glucagon.<ref name=":2" />
@@ Line 26: / Line 26: @@
 === Glucagon Secretion and Control of Gluconeogenesis ===
-Glucagon functions to signal the liver to begin [[gluconeogenesis]] which increases glucose levels in the blood.<ref name=":3" /> Glucagon will bind to the glucagon receptors on the plasma membranes of [[hepatocyte]]s (liver cells). This ligand binding causes the activation of [[Adenylyl cyclase|adenylate cyclase]], which causes the creation of [[Cyclic adenosine monophosphate|cyclic AMP]] (cAMP).<ref name=":4">{{Cite journal |last1=Janah |first1=Lina |last2=Kjeldsen |first2=Sasha |last3=Galsgaard |first3=Katrine D. |last4=Winther-Sørensen |first4=Marie |last5=Stojanovska |first5=Elena |last6=Pedersen |first6=Jens |last7=Knop |first7=Filip K. |last8=Holst |first8=Jens J. |last9=Wewer Albrechtsen |first9=Nicolai J. |date=January 2019 |title=Glucagon Receptor Signaling and Glucagon Resistance |journal=International Journal of Molecular Sciences |language=en |volume=20 |issue=13 |pages=3314 |doi=10.3390/ijms20133314 |issn=1422-0067 |pmc=6651628 |pmid=31284506|doi-access=free }}</ref> As the intracellular concentration of cAMP rises, [[protein kinase A]] (PKA) is activated and phosphorylates the transcription factor [[CREB|cAMP Response Element Binding]] (CREB) protein.<ref name=":4" /> CREB then induces transcription of [[Glucose 6-phosphatase|glucose-6-phosphatase]] and [[phosphoenolpyruvate carboxylase]] (PEPCK). These enzymes increase gluconeogenic activity.<ref name=":4" /> PKA also phosphorylates [[Phosphofructokinase 2|phospho-fructokinase 2]] (PFK2)/fructose 2,6-biphsophatase (FBPase2), inhibiting PFK2 and activating FBPase2.<ref name=":4" /> This inhibition decreases intracellular levels of [[Fructose 2,6-bisphosphate|fructose 2,6-biphosphate]] and increases intracellular levels of [[fructose 6-phosphate]] which decreases glycolytic activity and increases gluconeogenic activity.<ref name=":4" /> PKA also phosphorylates [[pyruvate kinase]] which causes an increase in intracellular levels of fructose 1,6-biphosphate and decreases intracellular levels of pyruvate, further decreasing glycolytic activity.<ref name=":4" /> The most important action of PKA in regulating gluconeogenesis is the phosphorylation of phosphorylase kinase which acts to initiate the [[glycogenolysis]] reaction, which is the conversion of [[glycogen]] to glucose, by converting glycogen to glucose 1-phosphate.<ref name=":4" />
+Glucagon functions to signal the liver to begin [[gluconeogenesis]] which increases glucose levels in the blood.<ref name=":3" /> Glucagon will bind to the glucagon receptors on the plasma membranes of [[hepatocyte]]s (liver cells). This ligand binding causes the activation of [[Adenylyl cyclase|adenylate cyclase]], which causes the creation of [[Cyclic adenosine monophosphate|cyclic AMP]] (cAMP).<ref name=":4">{{Cite journal |last1=Janah |first1=Lina |last2=Kjeldsen |first2=Sasha |last3=Galsgaard |first3=Katrine D. |last4=Winther-Sørensen |first4=Marie |last5=Stojanovska |first5=Elena |last6=Pedersen |first6=Jens |last7=Knop |first7=Filip K. |last8=Holst |first8=Jens J. |last9=Wewer Albrechtsen |first9=Nicolai J. |date=January 2019 |title=Glucagon Receptor Signaling and Glucagon Resistance |journal=International Journal of Molecular Sciences |language=en |volume=20 |issue=13 |page=3314 |doi=10.3390/ijms20133314 |issn=1422-0067 |pmc=6651628 |pmid=31284506|doi-access=free }}</ref> As the intracellular concentration of cAMP rises, [[protein kinase A]] (PKA) is activated and phosphorylates the transcription factor [[CREB|cAMP Response Element Binding]] (CREB) protein.<ref name=":4" /> CREB then induces transcription of [[Glucose 6-phosphatase|glucose-6-phosphatase]] and [[phosphoenolpyruvate carboxylase]] (PEPCK). These enzymes increase gluconeogenic activity.<ref name=":4" /> PKA also phosphorylates [[Phosphofructokinase 2|phospho-fructokinase 2]] (PFK2)/fructose 2,6-biphsophatase (FBPase2), inhibiting PFK2 and activating FBPase2.<ref name=":4" /> This inhibition decreases intracellular levels of [[Fructose 2,6-bisphosphate|fructose 2,6-biphosphate]] and increases intracellular levels of [[fructose 6-phosphate]] which decreases glycolytic activity and increases gluconeogenic activity.<ref name=":4" /> PKA also phosphorylates [[pyruvate kinase]] which causes an increase in intracellular levels of fructose 1,6-biphosphate and decreases intracellular levels of pyruvate, further decreasing glycolytic activity.<ref name=":4" /> The most important action of PKA in regulating gluconeogenesis is the phosphorylation of phosphorylase kinase which acts to initiate the [[glycogenolysis]] reaction, which is the conversion of [[glycogen]] to glucose, by converting glycogen to glucose 1-phosphate.<ref name=":4" />
 Alpha cells also generate [[Glucagon-like peptide-1]] and may have protective and regenerative effect on [[beta cell]]s. They possibly can [[Transdifferentiation|transdifferentiate]] into beta cells to replace lost beta cells.<ref>{{Cite journal|last1=Stanojevic|first1=Violeta|last2=Habener|first2=Joel F.|date=2015-10-08|title=Evolving Function and Potential of Pancreatic Alpha Cells|journal=Best Practice & Research. Clinical Endocrinology & Metabolism|volume=29|issue=6|pages=859–871|doi=10.1016/j.beem.2015.10.002|issn=1521-690X|pmc=4690008|pmid=26696515}}</ref>
@@ Line 34: / Line 34: @@
 === Neuronal Control ===
-The most well studied is through the action of extra-pancreatic glucose sensors, including neurons found in the brain, which exert control over the alpha cells in the pancreas.<ref name=":3" /> The pancreas is controlled by both the [[sympathetic nervous system]] and the [[parasympathetic nervous system]], although the method these two systems use to control the pancreas appears to be different.<ref name=":5">{{Cite journal |last1=Verberne |first1=Anthony J. M. |last2=Mussa |first2=Bashair M. |date=2022-06-01 |title=Neural control of pancreatic peptide hormone secretion |url=https://www.sciencedirect.com/science/article/pii/S0196978122000341 |journal=Peptides |language=en |volume=152 |pages=170768 |doi=10.1016/j.peptides.2022.170768 |pmid=35189258 |s2cid=246906606 |issn=0196-9781|url-access=subscription }}</ref>
+The most well studied is through the action of extra-pancreatic glucose sensors, including neurons found in the brain, which exert control over the alpha cells in the pancreas.<ref name=":3" /> The pancreas is controlled by both the [[sympathetic nervous system]] and the [[parasympathetic nervous system]], although the method these two systems use to control the pancreas appears to be different.<ref name=":5">{{Cite journal |last1=Verberne |first1=Anthony J. M. |last2=Mussa |first2=Bashair M. |date=2022-06-01 |title=Neural control of pancreatic peptide hormone secretion |url=https://www.sciencedirect.com/science/article/pii/S0196978122000341 |journal=Peptides |language=en |volume=152 |article-number=170768 |doi=10.1016/j.peptides.2022.170768 |pmid=35189258 |s2cid=246906606 |issn=0196-9781|url-access=subscription }}</ref>
 Sympathetic control of the pancreas appears to originate from the sympathetic preganglionic fibers in the lower thoracic and lumbar spinal cord.<ref name=":6">{{Cite journal |first1=Tanja |last1=Babic |first2=R. Alberto |last2=Travagli |date=2016-09-23 |title=Neural Control of the Pancreas |url=https://pancreapedia.org/reviews/neural-control-of-pancreas |journal=Pancreapedia: The Exocrine Pancreas Knowledge Base |language=en |doi=10.3998/panc.2016.27|doi-access=free }}</ref> According to Travagli et al. "axons from these neurons exit the spinal cord through the [[Ventral root of spinal nerve|ventral roots]] and supply either the [[paravertebral ganglia]] of the sympathetic chain via communicating rami of the thoracic and lumbar nerves, or the celiac and mesenteric ganglia via the [[splanchnic nerves]]. The catecholaminergic neurons of these ganglia innervate the intrapancreatic ganglia, islets and blood vessels..."<ref name=":6" /> The exact nature of the effect of sympathetic activation on the pancreas has been difficult to discern. However, a few things are known. It appears that stimulation of the splanchnic nerve lowers plasma insulin levels possibly through the action of α2 adrenoreceptors on beta cells.<ref name=":6" /> It has also been shown that stimulation of the splanchnic nerve increases glucagon secretion.<ref name=":6" /> Both of these findings together suggest that sympathetic stimulation of the pancreas is meant to maintain blood glucose levels during heightened arousal.<ref name=":6" />
@@ Line 45: / Line 45: @@
 Zinc is secreted at the same time as insulin by the beta cells in the pancreas. It has been proposed to act as a paracrine signal to inhibit glucagon secretion in alpha cells. Zinc is transported into both alpha and beta cells by the zinc transporter [[Zinc transporter 8|ZnT8]]. This protein channel allows zinc to cross the plasma membrane into the cell. When ZnT8 is under-expressed, there is a marked increase in glucagon secretion. When ZnT8 is over-expressed, there is a marked decrease in glucagon secretion. The exact mechanism by which zinc inhibits glucagon secretion is not known.<ref>{{Cite journal |last1=Rutter |first1=Guy A. |last2=Chabosseau |first2=Pauline |last3=Bellomo |first3=Elisa A. |last4=Maret |first4=Wolfgang |last5=Mitchell |first5=Ryan K. |last6=Hodson |first6=David J. |last7=Solomou |first7=Antonia |last8=Hu |first8=Ming |date=February 2016 |title=Intracellular zinc in insulin secretion and action: a determinant of diabetes risk? |journal=Proceedings of the Nutrition Society |language=en |volume=75 |issue=1 |pages=61–72 |doi=10.1017/S0029665115003237 |pmid=26365743 |s2cid=13936539 |issn=0029-6651|doi-access=free }}</ref>
-Insulin has been shown to function as a paracrine signal to inhibit glucagon secretion by the alpha cells.<ref>{{Cite journal |last1=Asplin |first1=C. M. |last2=Paquette |first2=T. L. |last3=Palmer |first3=J. P. |date=1981-07-01 |title=In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. |url=https://www.jci.org/articles/view/110251 |journal=The Journal of Clinical Investigation |language=en |volume=68 |issue=1 |pages=314–318 |doi=10.1172/JCI110251 |issn=0021-9738 |pmc=370801 |pmid=7019246}}</ref> However, this is not through a direct interaction. It appears that insulin functions to inhibit glucagon secretion through activation of delta cells to secrete somatostatin.<ref name=":7">{{Cite journal |last1=Vergari |first1=Elisa |last2=Knudsen |first2=Jakob G. |last3=Ramracheya |first3=Reshma |last4=Salehi |first4=Albert |last5=Zhang |first5=Quan |last6=Adam |first6=Julie |last7=Asterholm |first7=Ingrid Wernstedt |last8=Benrick |first8=Anna |last9=Briant |first9=Linford J. B. |last10=Chibalina |first10=Margarita V. |last11=Gribble |first11=Fiona M. |date=2019-01-11 |title=Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion |journal=Nature Communications |language=en |volume=10 |issue=1 |pages=139 |doi=10.1038/s41467-018-08193-8 |issn=2041-1723 |pmc=6329806 |pmid=30635569|bibcode=2019NatCo..10..139V }}</ref> Insulin binds to [[Sodium/glucose cotransporter 2|SGLT2]] causing an increased glucose uptake into delta cells. SGLT2 is a sodium and glucose [[symporter]], meaning that it brings glucose and sodium ions across the membrane at the same time in the same direction. This influx of sodium ions, in the right conditions, can cause a depolarization event across the membrane. This opens calcium channels, causing intracellular calcium levels to increase. This increase in the concentration of calcium in the cytosol activates [[ryanodine receptor]]s on the [[endoplasmic reticulum]] which causes the release of more calcium into the cytosol. This increase in calcium causes the secretion of somatostatin by the delta cells.<ref name=":7" />
+Insulin has been shown to function as a paracrine signal to inhibit glucagon secretion by the alpha cells.<ref>{{Cite journal |last1=Asplin |first1=C. M. |last2=Paquette |first2=T. L. |last3=Palmer |first3=J. P. |date=1981-07-01 |title=In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. |url=https://www.jci.org/articles/view/110251 |journal=The Journal of Clinical Investigation |language=en |volume=68 |issue=1 |pages=314–318 |doi=10.1172/JCI110251 |issn=0021-9738 |pmc=370801 |pmid=7019246}}</ref> However, this is not through a direct interaction. It appears that insulin functions to inhibit glucagon secretion through activation of delta cells to secrete somatostatin.<ref name=":7">{{Cite journal |last1=Vergari |first1=Elisa |last2=Knudsen |first2=Jakob G. |last3=Ramracheya |first3=Reshma |last4=Salehi |first4=Albert |last5=Zhang |first5=Quan |last6=Adam |first6=Julie |last7=Asterholm |first7=Ingrid Wernstedt |last8=Benrick |first8=Anna |last9=Briant |first9=Linford J. B. |last10=Chibalina |first10=Margarita V. |last11=Gribble |first11=Fiona M. |date=2019-01-11 |title=Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion |journal=Nature Communications |language=en |volume=10 |issue=1 |page=139 |doi=10.1038/s41467-018-08193-8 |issn=2041-1723 |pmc=6329806 |pmid=30635569|bibcode=2019NatCo..10..139V }}</ref> Insulin binds to [[Sodium/glucose cotransporter 2|SGLT2]] causing an increased glucose uptake into delta cells. SGLT2 is a sodium and glucose [[symporter]], meaning that it brings glucose and sodium ions across the membrane at the same time in the same direction. This influx of sodium ions, in the right conditions, can cause a depolarization event across the membrane. This opens calcium channels, causing intracellular calcium levels to increase. This increase in the concentration of calcium in the cytosol activates [[ryanodine receptor]]s on the [[endoplasmic reticulum]] which causes the release of more calcium into the cytosol. This increase in calcium causes the secretion of somatostatin by the delta cells.<ref name=":7" />
 Somatostatin inhibits glucagon secretion through the activation of [[Somatostatin receptor 2|SSTR2]], a membrane bound protein that when activated causes a hyperpolarization of the membrane. This hyperpolarization causes voltage gated calcium channels to close, leading to a decrease in intracellular calcium levels. This causes a decrease in exocytosis. In the case of alpha cells, this causes a decrease in the secretion of glucagon.<ref>{{Cite journal |last1=Kailey |first1=Balrik |last2=van de Bunt |first2=Martijn |last3=Cheley |first3=Stephen |last4=Johnson |first4=Paul R. |last5=MacDonald |first5=Patrick E. |last6=Gloyn |first6=Anna L. |last7=Rorsman |first7=Patrik |last8=Braun |first8=Matthias |date=2012-11-01 |title=SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells |journal=American Journal of Physiology. Endocrinology and Metabolism |language=en |volume=303 |issue=9 |pages=E1107–E1116 |doi=10.1152/ajpendo.00207.2012 |issn=0193-1849 |pmc=3492856 |pmid=22932785}}</ref>
@@ Line 57: / Line 57: @@
 === Type I Diabetes ===
-It is thought that high glucagon levels and lack of insulin production are the main triggers for the metabolic issues associated with [[Type 1 diabetes|Type I diabetes]], in particular maintaining normal blood glucose levels, formation of ketone bodies, and formation of urea.<ref name=":8">{{Cite journal |last1=Bisgaard Bengtsen |first1=Mads |last2=Møller |first2=Niels |date=August 2021 |title=Mini‐review: Glucagon responses in type 1 diabetes – a matter of complexity |journal=Physiological Reports |language=en |volume=9 |issue=16 |pages=e15009 |doi=10.14814/phy2.15009 |issn=2051-817X |pmc=8371343 |pmid=34405569}}</ref> One finding of note is that the glucagon response to hypoglycemia is completely absent in patients with Type I diabetes.<ref name=":8" /> Consistently high glucagon concentrations in the blood can lead to diabetic ketoacidosis,<ref name=":8" /> which is when ketones from lipid breakdown build up in the blood, which can lead to dangerously low blood glucose levels, low potassium levels, and in extreme cases cerebral edema.<ref>{{Cite web |title=Diabetic ketoacidosis - Symptoms and causes |url=https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551 |access-date=2022-03-22 |website=Mayo Clinic |language=en}}</ref> It has been proposed that the reason for the high levels of glucagon found in the plasma of patients with Type I diabetes is the absence of beta cells producing insulin and the reciprocal effect this has on delta cells and the secretion of somatostatin.<ref name=":8" />
+It is thought that high glucagon levels and lack of insulin production are the main triggers for the metabolic issues associated with [[Type 1 diabetes|Type I diabetes]], in particular maintaining normal blood glucose levels, formation of ketone bodies, and formation of urea.<ref name=":8">{{Cite journal |last1=Bisgaard Bengtsen |first1=Mads |last2=Møller |first2=Niels |date=August 2021 |title=Mini‐review: Glucagon responses in type 1 diabetes – a matter of complexity |journal=Physiological Reports |language=en |volume=9 |issue=16 |article-number=e15009 |doi=10.14814/phy2.15009 |issn=2051-817X |pmc=8371343 |pmid=34405569}}</ref> One finding of note is that the glucagon response to hypoglycemia is completely absent in patients with Type I diabetes.<ref name=":8" /> Consistently high glucagon concentrations in the blood can lead to diabetic ketoacidosis,<ref name=":8" /> which is when ketones from lipid breakdown build up in the blood, which can lead to dangerously low blood glucose levels, low potassium levels, and in extreme cases cerebral edema.<ref>{{Cite web |title=Diabetic ketoacidosis - Symptoms and causes |url=https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551 |access-date=2022-03-22 |website=Mayo Clinic |language=en}}</ref> It has been proposed that the reason for the high levels of glucagon found in the plasma of patients with Type I diabetes is the absence of beta cells producing insulin and the reciprocal effect this has on delta cells and the secretion of somatostatin.<ref name=":8" />
 === Type II Diabetes ===
-Patients with Type II diabetes will have elevated glucagon levels during a fast and after eating.<ref name=":9">{{Cite journal |last1=Lund |first1=Asger |last2=Bagger |first2=Jonatan I. |last3=Christensen |first3=Mikkel |last4=Knop |first4=Filip K. |last5=Vilsbøll |first5=Tina |date=December 2014 |title=Glucagon and Type 2 Diabetes: the Return of the Alpha Cell |url=http://link.springer.com/10.1007/s11892-014-0555-4 |journal=Current Diabetes Reports |language=en |volume=14 |issue=12 |pages=555 |doi=10.1007/s11892-014-0555-4 |pmid=25344790 |s2cid=6159190 |issn=1534-4827|url-access=subscription }}</ref> These elevated glucagon levels over stimulate the liver to undergo gluconeogenesis, leading to elevated blood glucose levels.<ref name=":9" /> Consistently high blood glucose levels can lead to organ damage, neuropathy, blindness, cardiovascular issues and bone and joint problems.<ref>{{Cite web |title=Hyperglycemia in diabetes - Symptoms and causes |url=https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631 |access-date=2022-03-22 |website=Mayo Clinic |language=en}}</ref> It is not entirely clear why glucagon levels are so high in patients with Type II diabetes. One theory is that the alpha cells have become resistant to the inhibitory effects of glucose and insulin and do not respond properly to them.<ref name=":9" /> Another theory is that nutrient stimulation of the gastrointestinal tract, thus the secretion of [[gastric inhibitory polypeptide]] and [[Glucagon-like peptide-1]], is a very important factor in the elevated secretion of glucagon.<ref name=":9" />
+Patients with Type II diabetes will have elevated glucagon levels during a fast and after eating.<ref name=":9">{{Cite journal |last1=Lund |first1=Asger |last2=Bagger |first2=Jonatan I. |last3=Christensen |first3=Mikkel |last4=Knop |first4=Filip K. |last5=Vilsbøll |first5=Tina |date=December 2014 |title=Glucagon and Type 2 Diabetes: the Return of the Alpha Cell |url=http://link.springer.com/10.1007/s11892-014-0555-4 |journal=Current Diabetes Reports |language=en |volume=14 |issue=12 |page=555 |doi=10.1007/s11892-014-0555-4 |pmid=25344790 |s2cid=6159190 |issn=1534-4827|url-access=subscription }}</ref> These elevated glucagon levels over stimulate the liver to undergo gluconeogenesis, leading to elevated blood glucose levels.<ref name=":9" /> Consistently high blood glucose levels can lead to organ damage, neuropathy, blindness, cardiovascular issues and bone and joint problems.<ref>{{Cite web |title=Hyperglycemia in diabetes - Symptoms and causes |url=https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631 |access-date=2022-03-22 |website=Mayo Clinic |language=en}}</ref> It is not entirely clear why glucagon levels are so high in patients with Type II diabetes. One theory is that the alpha cells have become resistant to the inhibitory effects of glucose and insulin and do not respond properly to them.<ref name=":9" /> Another theory is that nutrient stimulation of the gastrointestinal tract, thus the secretion of [[gastric inhibitory polypeptide]] and [[Glucagon-like peptide-1]], is a very important factor in the elevated secretion of glucagon.<ref name=":9" />
 == In other species ==
@@ Line 73: / Line 73: @@
 <ref name="Jacobson-Shyng-2020">{{cite journal | last1=Jacobson | first1=David A. | last2=Shyng | first2=Show-Ling | title=Ion Channels of the Islets in Type 2 Diabetes | journal=[[Journal of Molecular Biology]] | publisher=[[Elsevier]] | volume=432 | issue=5 | year=2020 | issn=0022-2836 | doi=10.1016/j.jmb.2019.08.014 | pages=1326–1346 | pmc=7720859 | pmid=31473158 | s2cid=201715726}} [[NIH Manuscript Submission|NIHMSID]] 1538588.</ref>
 <ref name="Kasaragod-et-al-2019">{{cite journal | last1=Kasaragod | first1=Vikram Babu | last2=Hausrat | first2=Torben Johann | last3=Schaefer | first3=Natascha | last4=Kuhn | first4=Maximilian | last5=Christensen | first5=Nikolaj Riis | last6=Tessmer | first6=Ingrid | last7=Maric | first7=Hans Michael | last8=Madsen | first8=Kenneth Lindegaard | last9=Sotriffer | first9=Christoph | last10=Villmann | first10=Carmen | last11=Kneussel | first11=Matthias | last12=Schindelin | first12=Hermann | title=Elucidating the Molecular Basis for Inhibitory Neurotransmission Regulation by Artemisinins | journal=[[Neuron (journal)|Neuron]] | publisher=[[Cell Press]] | volume=101 | issue=4 | year=2019 | issn=0896-6273 | doi=10.1016/j.neuron.2019.01.001 | pages=673–689.e11 | pmid=30704910 | s2cid=72332955| doi-access=free }}</ref>
-<ref name="Vuilleumier-Gauthier-2020">{{cite journal | last1=Cobo-Vuilleumier | first1=Nadia | last2=Gauthier | first2=Benoit R. | title=Time for a paradigm shift in treating type 1 diabetes mellitus: coupling inflammation to islet regeneration | journal=[[Metabolism (journal)|Metabolism]] | publisher=[[Elsevier]] | volume=104 | year=2020 | issn=0026-0495 | doi=10.1016/j.metabol.2020.154137 | page=154137 | s2cid=209894697 | pmid=31904355| doi-access=free | hdl=10261/221297 | hdl-access=free }}</ref>
+<ref name="Vuilleumier-Gauthier-2020">{{cite journal | last1=Cobo-Vuilleumier | first1=Nadia | last2=Gauthier | first2=Benoit R. | title=Time for a paradigm shift in treating type 1 diabetes mellitus: coupling inflammation to islet regeneration | journal=[[Metabolism (journal)|Metabolism]] | publisher=[[Elsevier]] | volume=104 | year=2020 | issn=0026-0495 | doi=10.1016/j.metabol.2020.154137 | article-number=154137 | s2cid=209894697 | pmid=31904355| doi-access=free | hdl=10261/221297 | hdl-access=free }}</ref>
 <ref name="Lorenzo-et-al-2018">{{cite journal | last1=Lorenzo | first1=Petra I | last2=Cobo-Vuilleumier | first2=Nadia | last3=Gauthier | first3=Benoit R | title=Therapeutic potential of pancreatic PAX4-regulated pathways in treating diabetes mellitus | journal=[[Current Opinion in Pharmacology]] | publisher=[[Elsevier]] | volume=43 | year=2018 | issn=1471-4892 | doi=10.1016/j.coph.2018.07.004 | pages=1–10 | pmid=30048825 | s2cid=51723745}}</ref>
 <ref name="Zhang-Liu-2020">{{cite journal | last1=Zhang | first1=Jingjing | last2=Liu | first2=Feng | title=The De-, Re-, and trans-differentiation of β-cells: Regulation and function | journal=[[Seminars in Cell & Developmental Biology]] | publisher=[[Elsevier]] | volume=103 | year=2020 | issn=1084-9521 | doi=10.1016/j.semcdb.2020.01.003 | pages=68–75 | pmid=31948775 | s2cid=210702856}}</ref>
@@ Line 112: / Line 112: @@
 <ref name="Kim-Hibbs-2019" />
 <ref name="Michelena-et-al-2021" />
-<ref name="Coppieters-et-al-2020">{{cite book | last1=Coppieters | first1=Ken | last2=von Herrath | first2=Matthias | last3=Homann | first3=Dirk | title=The Autoimmune Diseases | chapter=Animal Models of Organ-Specific Autoimmune Disease | publisher=[[Elsevier]] | year=2020 | doi=10.1016/b978-0-12-812102-3.00027-0 | pages=493–511 | isbn=9780128121023 | s2cid=243055640 | editor1-first=Noel R. | editor1-last=Rose | editor2-first=Ian R. | editor2-last=Mackay}}</ref>
+<ref name="Coppieters-et-al-2020">{{cite book | last1=Coppieters | first1=Ken | last2=von Herrath | first2=Matthias | last3=Homann | first3=Dirk | title=The Autoimmune Diseases | chapter=Animal Models of Organ-Specific Autoimmune Disease | publisher=[[Elsevier]] | year=2020 | doi=10.1016/b978-0-12-812102-3.00027-0 | pages=493–511 | isbn=978-0-12-812102-3 | s2cid=243055640 | editor1-first=Noel R. | editor1-last=Rose | editor2-first=Ian R. | editor2-last=Mackay}}</ref>
 }} and van der Meulen ''et al.'', 2018 find the same absence of effect for [[artemether]]{{rr|Artemether-bundle|r=
 <ref name="Eizirik-Gurzov-2018" />

Alpha cell: Difference between revisions

Latest revision as of 11:32, 21 October 2025

Contents

Discovery

Anatomy

Function

Glucagon Secretion and Control of Gluconeogenesis

Regulation of glucagon secretion

Neuronal Control

Non-neuronal Control

Medical significance

Type I Diabetes

Type II Diabetes

In other species

See also

References

Further reading

Navigation menu

Alpha cell: Difference between revisions

Latest revision as of 11:32, 21 October 2025

Discovery

Anatomy

Function

Glucagon Secretion and Control of Gluconeogenesis

Regulation of glucagon secretion

Neuronal Control

Non-neuronal Control

Medical significance

Type I Diabetes

Type II Diabetes

In other species

See also

References

Further reading

Navigation menu

Search